ArticleSensors and actuators reports2025
FRET-based reporter assesses lysosomal DNA-degradation ability in live cells.
Article in Sensors and actuators reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a selective-iodide indicator for live-cell imaging and evaluation of CFTR activity.Sensors & diagnostics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Lysosomes are multifunctional organelles that serve as the cell's central hub for metabolic signaling. Lysosomal malfunction disrupts intracellular homeostasis, leading to adverse health effects. Therefore, assessing lysosomal function is vital for advancing disease understanding and guiding therapeutic development. The existing evaluation methods rely primarily on monitoring lysosomal pH and protein degradation. Here we introduce a DNA-based reporter to evaluate lysosomal activity by assessing the DNA-degradation ability of lysosomes using fluorescence imaging. We successfully monitored the lysosomal DNA-degradation ability in dysregulated lysosomes and lysosomes in drug-induced disease model of NP-A/B and NP-C. We found that both pharmacologically induced models resulted in significant reduction in lysosomal DNA-degradation ability. This tool for monitoring lysosomal activity offers valuable insights for both therapeutic development and understanding disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.